Medicamen Biotech Ltd. (MEDICAM) Share Price Falls 9.22%: Price Action, Valuation and Sector View

Medicamen Biotech Ltd. fell to Rs 218.55, down 9.22% today. The micro cap healthcare stock has a market capitalisation of Rs 326.52 crore.

Medicamen Biotech Ltd. Share Price fell to Rs 218.55 on 17 August 2026, down 9.22% from the previous close of Rs 240.75, taking the company’s market capitalisation to Rs 326.52 crore. For investors tracking Medicamen Biotech Ltd. Share Price Today, the move stood out because it placed the stock among the notable top decliner names in its segment during the session.

The stock opened at Rs 240.95, which was also the day’s high, and then weakened to an intraday low of Rs 214.90 before settling near those lower levels. That kind of price path matters because it shows that the session began without a gap-down shock of a very different order, but selling pressure intensified through the day. In Stock Market Today and Share Market Today conversations, such sessions usually attract attention not only for the percentage decline but also for how the intraday range develops.

The supplied data confirms the price fall but does not establish a company-specific catalyst behind the decline. Even so, the move is still relevant market news because MEDICAM belongs to the Micro Cap category, where sharper one-day changes can quickly put a stock into the Stocks in News and Top Losers Today basket. Univest notes that investors usually look next at turnover, trading volume, valuation multiples, profitability ratios and sector benchmarks to decide whether a price move is merely event-driven or part of a broader re-rating.

For Medicamen Biotech Ltd. Stock News readers, the important verified metrics to monitor next are the day’s volume split across BSE and NSE, the stock’s P/E and P/B relative to the Pharmaceuticals & Drugs benchmark, its ROE and ROCE profile, and whether today’s price action leaves the stock under closer watch on Univest.

Medicamen Biotech Ltd. (MEDICAM) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 218.55
Previous Close	Rs 240.75
Today's Change	Rs -22.2 (-9.22%)
Day Open	Rs 240.95
Day High	Rs 240.95
Day Low	Rs 214.9
Current Volume (BSE)	4,596
BSE Traded Volume	4,596
NSE Traded Volume	59,925
Combined NSE + BSE Volume	64,521
Turnover	Rs 0.1 crore
Market Capitalisation	Rs 326.52 crore
Market Cap Category	Micro Cap

Medicamen Biotech Ltd. (MEDICAM) traded at Rs 218.55. versus the previous close of Rs 240.75, a fall of 9.22%. The stock opened at Rs 240.95, reached Rs 240.95, touched Rs 214.9. Reported volume was 4,596.

Medicamen Biotech Ltd. (MEDICAM) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 326.52 crore
P/E Ratio	30.15x
P/B Ratio	1.21x
ROE	9.89%
ROCE	12.99%
EPS	Rs 7.98
Dividend Yield	0.42%

Medicamen Biotech Ltd. was valued at a P/E ratio of 30.15x, a P/B ratio of 1.21x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 9.89% and ROCE of 12.99%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 7.98, dividend yield of 0.42%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Medicamen Biotech Ltd. Fundamental Analysis shows a micro cap pharmaceutical company with moderate profitability ratios, a middle-range earnings multiple versus its industry benchmark and a relatively low price-to-book valuation. Those figures add context to today’s decline, even though they do not by themselves explain the session’s trigger.

At the current price action level, Medicamen Biotech Ltd. has a market capitalisation of Rs 326.52 crore. Its P/E ratio stands at 30.15, while the P/B ratio is 1.21. In fundamental analysis terms, the P/E reflects how the market values the company’s earnings, and the P/B shows how the stock is trading relative to its accounting net worth. On that basis, the stock is not trading at an unusually stretched book multiple when compared with many listed pharma names in the same industry snapshot.

Profitability metrics provide a second layer of context. Return on equity, or ROE, stands at 9.89%, while ROCE is 12.99%. These are useful measures because ROE captures return generated on shareholder equity and ROCE shows returns generated on capital employed. For Medicamen Biotech Ltd. Share Price watchers, those numbers indicate the company is generating positive returns, though the extent of that return still has to be judged against sector benchmarks and peers rather than in isolation.

EPS is Rs 7.98, which means the stock’s earnings attributable to each share are modest relative to the current trading price. Dividend yield stands at 0.42, giving the stock a small historical/current payout component. That dividend yield should be seen as a data point on distribution history rather than a forward income signal. Univest also tracks this combination carefully because a stock with a 30.15 P/E, 1.21 P/B, 9.89% ROE and 12.99% ROCE can invite very different interpretations depending on industry valuation bands.

Importantly, today’s share price decline does not automatically negate the company’s financial profile, nor do these ratios turn the move into a valuation call. Instead, Medicamen Biotech Ltd. Stock Analysis at this point is about balance: positive profitability, modest dividend yield, and a valuation setup that becomes more meaningful only when read beside the Healthcare and Pharmaceuticals & Drugs benchmark data. That naturally leads into the sector context.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	30.15x
Benchmark Median P/E	26.47x
Benchmark Average P/E	40.28x
Benchmark P/E Range	2.98x to 361.02x
Company P/B Ratio	1.21x
Benchmark Median P/B	1.77x
Company ROE	9.89%
Benchmark Median ROE	9.91%
Company ROCE	12.99%
Benchmark Median ROCE	12.79%
Company Market Capitalisation	Rs 326.52 crore
Benchmark Median Market Cap	Rs 137.8 crore

Medicamen Biotech Ltd. (MEDICAM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Medicamen Biotech Ltd. (MEDICAM) has a P/E ratio of 30.15x, which is above the benchmark median of 26.47x, a difference of +13.9%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Medicamen Biotech Ltd. (MEDICAM) has a ROE of 9.89%, which is below the benchmark median of 9.91%, a difference of -0.2%. Medicamen Biotech Ltd. (MEDICAM) has a ROCE of 12.99%, which is above the benchmark median of 12.79%, a difference of +1.56%.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Medicamen Biotech Ltd. operates in Healthcare and specifically in the Pharmaceuticals & Drugs industry. Against the same-industry benchmark of 139 companies, its valuation and profitability metrics sit close to some central ranges on returns, while its price-to-book ratio is below the industry median and average.

The sector snapshot supplied for Medicamen Biotech Ltd. Share Price News uses the same industry benchmark and covers 139 companies. Within that universe, the company’s P/E is 30.15. That compares with a benchmark median P/E of 26.47 and an average P/E of 40.28, based on 105 companies with available P/E data. The full P/E range runs from 2.98 to 361.02. This places Medicamen Biotech neither at the cheapest end nor among the most richly valued names on earnings, but somewhat above the median and below the average.

On book value multiples, the company’s P/B is 1.21, while the benchmark median is 1.77 and the average is 2.33 across 138 companies. The benchmark range extends from -21.33 to 27.19. From a sector analysis perspective, Medicamen Biotech Ltd. therefore screens below both the median and average P/B within Pharmaceuticals & Drugs.

Profitability presents a more mixed but informative picture. The company’s ROE is 9.89%, almost in line with the benchmark median ROE of 9.91% and above the benchmark average of 7.30 across 138 companies. Its ROCE of 12.99% is slightly above the benchmark median ROCE of 12.79% but below the average ROCE of 14.83. In market capitalisation terms, the company at Rs 326.52 crore is above the industry median market cap of Rs 137.80 crore, yet below the average market cap of Rs 481.52 crore. The industry’s market-cap range spans Rs 2.19 crore to Rs 2,985.15 crore.

For Medicamen Biotech Ltd. Share Price Today, that benchmark context matters. The stock’s decline took place in a sector where its valuation is not at an extreme relative to industry averages, while its returns profile is broadly around the middle of the pack. Univest sees this as a useful filter for separating pure price action from deeper valuation questions.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,985.15	184.72	0.45	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,827.67	68.16	6.74	18.65	22.17
Hikal Ltd.	HIKAL	2,686.72	0	2.26	15.22	16.15
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,645.37	46.15	1.77	-0.78	8.31
Fredun Pharmaceuticals Ltd.	FREDUN	2,559.68	58.41	8.73	11.42	13.15

Medicamen Biotech Ltd. (MEDICAM) has a P/E ratio of 30.15x compared with the displayed peer median of 58.41x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 9.89% compares with a peer median of 11.42% across the companies shown in the table. ROCE stood at 12.99% versus the displayed peer median of 13.15%, providing a capital-efficiency comparison. Medicamen Biotech Ltd. (MEDICAM) has a market capitalisation of Rs 326.52 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Medicamen Biotech Ltd. compares against a wide Pharmaceuticals & Drugs peer set where market capitalisations are much larger, and valuation and profitability profiles vary sharply. The stock’s 30.15 P/E and 1.21 P/B place it below several higher-multiple peers, while its ROE and ROCE sit in the moderate range.

The peer snapshot shows how widely dispersed this industry is. Medicamen Biotech Ltd.’s market cap of Rs 326.52 crore is well below Dishman Carbogen Amcis Ltd. at Rs 2,985.15 crore, Beta Drugs Ltd. at Rs 2,827.67 crore, Hikal Ltd. at Rs 2,686.72 crore, Ind-Swift Laboratories Ltd. at Rs 2,645.37 crore and Fredun Pharmaceuticals Ltd. at Rs 2,559.68 crore. It is also smaller than Solara Active Pharma Sciences Ltd. at Rs 2,465.73 crore, Sai Parenteral's Ltd. at Rs 2,438.25 crore, Panacea Biotec Ltd. at Rs 2,429.20 crore, Venus Remedies Ltd. at Rs 2,388.41 crore and NGL Fine-Chem Ltd. at Rs 2,139.20 crore.

On valuation, Medicamen’s P/E of 30.15 is below Dishman Carbogen Amcis at 184.72, Beta Drugs at 68.16, Ind-Swift Laboratories at 46.15, Fredun Pharmaceuticals at 58.41, Sai Parenteral's at 171 and NGL Fine-Chem at 37.40, while it is above Venus Remedies at 20.56. Several peers in the supplied list do not have a P/E value shown, so the most useful point is that Medicamen sits somewhere in the lower-to-middle part of the displayed positive P/E spectrum.

Its P/B of 1.21 is above Dishman Carbogen Amcis at 0.45 but below Hikal at 2.26, Ind-Swift Laboratories at 1.77, Fredun at 8.73, Solara at 1.93, Sai Parenteral's at 3.13, Panacea Biotec at 2.90, Venus Remedies at 3.48 and NGL Fine-Chem at 6.15. In profitability terms, Medicamen’s ROE of 9.89% is stronger than Dishman’s -2.89%, Ind-Swift’s -0.78% and Panacea’s 0, roughly in line with Venus Remedies at 9.85%, but below Beta Drugs at 18.65%, Hikal at 15.22%, Fredun at 11.42%, Solara at 17.23%, Sai Parenteral's at 13.90% and NGL Fine-Chem at 27.90%.

ROCE comparison is similarly balanced. Medicamen’s 12.99% is above Dishman’s -0.26%, Ind-Swift’s 8.31%, Panacea’s 5.36% and Venus Remedies’ 7.89%, nearly equal to Sai Parenteral's at 12.97%, and below Beta Drugs at 22.17%, Hikal at 16.15%, Fredun at 13.15%, Solara at 15.34% and NGL Fine-Chem at 33.91%. For Univest readers, that leaves Medicamen as a smaller-cap industry participant with mid-range profitability and relatively restrained P/B valuation.

Why Investors Are Watching Medicamen Biotech Ltd.

Medicamen Biotech Ltd. Share Price is being watched because today’s 9.22% decline was large enough to push the stock into the market’s top decliner discussion, while its valuation and profitability data leave room for deeper interpretation rather than a one-line conclusion.

• Price action: The stock fell Rs 22.20 from Rs 240.75 to Rs 218.55 after opening at Rs 240.95 and hitting a low of Rs 214.90.
• Volume profile: Total volume reached 64,521 shares, including 4,596 on BSE and 59,925 on NSE, with turnover of Rs 0.10 crore.
• Technical context: The supplied RSI stands at 73.38, which is an elevated reading even after today’s decline and keeps price action under close observation.
• Fundamental context: The stock trades at 30.15 times earnings and 1.21 times book value, with ROE of 9.89%, ROCE of 12.99%, EPS of Rs 7.98 and dividend yield of 0.42.
• Sector positioning: Its P/B is below industry median and average, while ROE and ROCE are close to sector medians.

What investors may monitor next is whether Medicamen Biotech Ltd. Share Price stabilises after this sharp single-session decline, how trading volume behaves in follow-through sessions, and whether the stock continues to trade as a valuation outlier or reverts toward broader Pharmaceuticals & Drugs sector patterns. Univest highlights that the supplied data verifies the move, but not a specific catalyst.

About Medicamen Biotech Ltd.

Medicamen Biotech Ltd. is positioned within the Healthcare sector and the Pharmaceuticals & Drugs industry. Based on the verified data supplied for this article, the company belongs to the listed pharma universe that is being compared against 139 same-industry companies on valuation, profitability and market-cap metrics.

That context alone already says something important about the business profile investors are evaluating. Pharmaceutical companies are commonly tracked through earnings multiples such as P/E, balance-sheet multiples such as P/B, and return measures like ROE and ROCE because these figures help show how efficiently the business converts capital into profits. In the case of Medicamen Biotech, the market is currently valuing the company at a scale of Rs 326.52 crore, which makes it a micro cap participant in an industry that ranges from very small listed entities to peers with market values close to Rs 2,985.15 crore.

For readers following Medicamen Biotech Ltd. Latest News and Medicamen Biotech Ltd. Company News, the main business takeaway from the supplied dataset is its industry location: it is part of a Healthcare and Pharmaceuticals & Drugs peer group where valuation dispersion is wide and profitability quality varies significantly. That makes stock-specific analysis especially dependent on comparing the company’s P/E, P/B, ROE and ROCE with the broader industry field rather than viewing any one ratio in isolation. Univest therefore frames the stock as a micro cap pharma counter whose market behaviour should be studied alongside sector and peer context.

Track Medicamen Biotech Ltd. Share Price on Univest

Use Medicamen Biotech Ltd. (MEDICAM) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Investors who want to follow Medicamen Biotech Ltd. Share Price more closely can use Univest to monitor live share price moves, daily price action, market capitalisation, valuation ratios and profitability indicators in one place. The platform also helps users track shareholding pattern updates when available, 52-week levels, volume behaviour, sector comparisons and broader market insights around Stocks Falling Today and Market Movers.

For Medicamen Biotech Ltd. Share Price Today, that matters because one sharp decline can attract attention, but follow-through data often shapes the bigger picture. Univest allows users to keep watch on the stock’s latest market update, compare it with Healthcare peers and review whether future sessions show stabilisation, renewed weakness or changing participation levels across NSE and BSE.

Frequently Asked Questions

Why is Medicamen Biotech Ltd. Share Price falling today?

Ans. Medicamen Biotech Ltd. Share Price fell 9.22% to Rs 218.55 from the previous close of Rs 240.75. The supplied data confirms the decline and intraday weakness, but it does not establish any company-specific trigger behind today’s move.

What is Medicamen Biotech Ltd. Share Price Today?

Ans. Medicamen Biotech Ltd. Share Price Today was Rs 218.55 at the time of the article. That level was Rs 22.20 below the previous close of Rs 240.75, after the stock traded between Rs 240.95 and Rs 214.90 intraday.

How much did MEDICAM stock decline in today’s session?

Ans. MEDICAM declined by Rs 22.20 in absolute terms and by 9.22% in percentage terms during the session. The stock opened at Rs 240.95, which was also the day’s high, and later slipped to a low of Rs 214.90.

What does today’s volume show for Medicamen Biotech Ltd.?

Ans. Total traded volume stood at 64,521 shares, including 4,596 shares on BSE and 59,925 shares on NSE. Turnover was Rs 0.10 crore, showing active participation for a micro cap stock despite modest absolute rupee turnover.

What is the market capitalisation of Medicamen Biotech Ltd.?

Ans. Medicamen Biotech Ltd. had a market capitalisation of Rs 326.52 crore in this update. That places it in the Micro Cap category, which is relevant because today’s decline was large enough to qualify under the event screen for that group.

Is Medicamen Biotech Ltd. expensive on P/E and P/B basis?

Ans. The stock trades at a P/E of 30.15 and a P/B of 1.21. Versus the same-industry benchmark, its P/E is above the median of 26.47 but below the average of 40.28, while P/B is below both median and average.

How profitable is Medicamen Biotech Ltd. based on supplied ratios?

Ans. The company’s ROE is 9.89% and ROCE is 12.99%. Those figures are close to the industry medians of 9.91% for ROE and 12.79% for ROCE, though ROCE remains below the industry average of 14.83%.

What are the EPS and dividend yield of Medicamen Biotech Ltd.?

Ans. Medicamen Biotech Ltd. reported EPS of Rs 7.98 and dividend yield of 0.42 in the supplied dataset. EPS reflects earnings attributable to each share, while dividend yield shows the historical/current payout relative to the stock price.

How does Medicamen Biotech Ltd. compare with pharma peers?

Ans. Medicamen Biotech Ltd. is much smaller than peers such as Dishman Carbogen Amcis, Beta Drugs and Hikal on market cap. Its P/E of 30.15 is below several displayed peers, while ROE of 9.89% sits around the mid-range of the group.

What should investors monitor next in Medicamen Biotech Ltd. Stock News?

Ans. Investors may track whether Medicamen Biotech Ltd. Share Price stabilises after today’s decline, whether volume remains elevated in follow-through sessions, and how the stock’s 30.15 P/E, 1.21 P/B, 9.89% ROE and 12.99% ROCE compare with peers.